Facts

• Segment: Surgical
• Country: United States
• Founded: 2017
• Website: https://xcath.com

Profile sections

• Summary
• Market context
• Facts
• Funding
• Investors
• Context / Market Position
• Events
• Relationships
• Customers and deployments
• Sources

Summary

XCath develops robotic systems for endovascular procedures. Its technology is designed to help physicians remotely navigate guidewires and catheters during neurovascular and cardiovascular interventions, reducing radiation exposure and improving precision in minimally invasive care.

Market context

XCath is a credible surgical robotics company focused on one of the harder and higher-value intervention categories in medtech: neurovascular procedures. Its relevance comes from combining robotic catheter navigation with a clear clinical use case in stroke and aneurysm care, recent first-in-human progress, and fresh Series C funding aimed at commercialization. XCath develops neurovascular surgical robotics and steerable guidewire systems for robotic endovascular navigation and minimally invasive cerebrovascular intervention.

Facts

• Website: https://xcath.com
• HQ: Houston, United States
• Founded: 2017
• Segment: Surgical
• Known funding rounds: 2

Funding

• 2026-03-12 - Series C - $30M - XCath secures $30M Series C to advance neuro-endovascular surgical robotics - source: businesswire.com
• 2022-01-01 - Series B - $24M - XCath $24M Series B (Crescent Enterprises 2022 report) - source: crescententerprises.com

Investors

• Crescent Enterprises - Lead - Angel / Individual - 2 funding events - repeat backer - first seen 2022-01-01 - latest 2026-03-12
• Dr. Fred Moll - Participant - Unknown - 1 funding event - first seen 2026-03-12

Neurovascular surgical robotics

XCath develops neuro-endovascular robotics and steerable guidewire systems for minimally invasive cerebrovascular intervention.

• Target environment: Stroke, aneurysm and neurovascular procedure workflows in interventional suites.
• Deployment model: Surgical robotics model focused on robotic catheter/guidewire navigation and physician-controlled intervention.
• Customer context: Neurointerventional physicians, hospitals and medtech partners seeking greater precision and access in complex vascular procedures.
• Workflow context: The platform supports robotic navigation through blood vessels for minimally invasive cerebrovascular treatment.
• Commercial maturity: Clinical-stage surgical robotics company with high-value neurovascular focus.
• Market position: Positioned in a difficult specialist procedure category rather than broad hospital automation.
• Adoption constraints: Adoption depends on clinical outcomes, regulatory progress, physician workflow fit, training and hospital purchasing.
• Adjacent context: Adjacent systems include endovascular robotics, surgical navigation tools, catheter systems and interventional stroke technologies.
• Source confidence: high

Events

• 2026-03-12 - Funding - XCath secures $30M Series C to advance neuro-endovascular surgical robotics - XCath announced a $30M Series C to support development and future commercialization of its endovascular surgical robot.
• 2025-11-12 - Production Milestone - XCath EVR robotic system performs first-in-human brain aneurysm procedures - XCath announced first-in-human use of its EVR robotic system to treat three patients with complex brain an…
• 2022-01-01 - Funding - XCath $24M Series B (Crescent Enterprises 2022 report) - XCath raised additional funding, bringing total capital raised to $24M; Crescent Enterprises cited the round in its 2022 sustainability rep…

Relationships

• deployment - XCath EVR was used for first-in-human brain aneurysm procedures at The Panama Clinic.

Customers and deployments

• Patient Count - 3 patients - 2025-11-12 - The Panama Clinic - clinical neurovascular procedures - XCath announced first-in-human use of its EVR robotic system to treat three patients with complex brain aneurysms at The…